Prof Simon Rule (Derriford Hospital, Plymouth, UK) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses recent advances in the treatment of patients with mantle cell lymphoma (MCL), including the phase 2 SPRINT study of lenalidomide versus investigator’s choice in relapsed or refractory MCL and a phase 2 study of lenalidomide plus rituximab as initial treatment in MCL.
This programme has been supported by sponsorship from Celgene.
